subject area of
- ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis Journal Articles
- Assessment of Alectinib vs Ceritinib in ALK-Positive Non–Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data Journal Articles
- Canadian Anaplastic Lymphoma Kinase Study: A Model for Multicenter Standardization and Optimization of ALK Testing in Lung Cancer Journal Articles
- Canadian Perspectives: Update on Inhibition of ALK-Positive Tumours in Advanced Non-Small-Cell Lung Cancer Journal Articles
- Developing ALK Immunohistochemistry and In Situ Hybridization Proficiency Testing for Non–Small Cell Lung Cancer in Canada Journal Articles
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Journal Articles
- Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience Journal Articles
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Journal Articles
- Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma Journal Articles
- Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline Journal Articles